Latest Insider Transactions at Emergent Bio Solutions Inc. (EBS)
This section provides a real-time view of insider transactions for Emergent Bio Solutions Inc. (EBS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Emergent BioSolutions Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Emergent BioSolutions Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 15
2024
|
Richard S Lindahl EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+8.06%
|
-
|
|
Jul 11
2024
|
Jennifer Lynne Fox EVP, Ext Aff, GC, Corp Sec |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+7.45%
|
-
|
|
Jul 11
2024
|
William Hartzel SVP, Bioservices |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+23.77%
|
-
|
|
Jul 08
2024
|
Paul Anthony Williams SVP, Products Business |
SELL
Payment of exercise price or tax liability
|
Direct |
85
-0.35%
|
$680
$8.13 P/Share
|
|
Jun 08
2024
|
William Hartzel SVP, Bioservices |
SELL
Payment of exercise price or tax liability
|
Direct |
1,167
-3.4%
|
$7,002
$6.19 P/Share
|
|
Jun 08
2024
|
Richard S Lindahl EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,733
-1.72%
|
$16,398
$6.19 P/Share
|
|
Jun 08
2024
|
Coleen Glessner EVP, Quality & Ethics, and CPL |
SELL
Payment of exercise price or tax liability
|
Direct |
1,249
-0.76%
|
$7,494
$6.19 P/Share
|
|
Jun 08
2024
|
Paul Anthony Williams SVP, Products Business |
SELL
Payment of exercise price or tax liability
|
Direct |
464
-1.86%
|
$2,784
$6.19 P/Share
|
|
Jun 08
2024
|
Jennifer Lynne Fox EVP, Ext Aff, GC, Corp Sec |
SELL
Payment of exercise price or tax liability
|
Direct |
2,376
-1.37%
|
$14,256
$6.19 P/Share
|
|
Jun 04
2024
|
Kathryn C Zoon Director |
SELL
Open market or private sale
|
Direct |
10,000
-15.51%
|
$60,000
$6.11 P/Share
|
|
May 29
2024
|
Kathryn C Zoon Director |
SELL
Open market or private sale
|
Direct |
1,830
-2.76%
|
$7,320
$4.61 P/Share
|
|
May 23
2024
|
Sujata Tyagi Dayal Director |
BUY
Grant, award, or other acquisition
|
Direct |
17,430
+21.64%
|
-
|
|
May 23
2024
|
Marvin L White Director |
BUY
Grant, award, or other acquisition
|
Direct |
17,430
+20.31%
|
-
|
|
May 23
2024
|
Donald W De Golyer Director |
BUY
Grant, award, or other acquisition
|
Direct |
17,430
+11.35%
|
-
|
|
May 23
2024
|
Neal Franklin Fowler Director |
BUY
Grant, award, or other acquisition
|
Direct |
17,430
+11.35%
|
-
|
|
May 23
2024
|
Keith Katkin Director |
BUY
Grant, award, or other acquisition
|
Direct |
17,430
+22.55%
|
-
|
|
May 23
2024
|
Kathryn C Zoon Director |
BUY
Grant, award, or other acquisition
|
Direct |
17,430
+20.81%
|
-
|
|
May 23
2024
|
Zsolt Harsanyi Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
17,430
+16.33%
|
-
|
|
May 23
2024
|
Louis W Sullivan Director |
BUY
Grant, award, or other acquisition
|
Direct |
17,430
+14.27%
|
-
|
|
May 23
2024
|
Ronald Richard Director |
BUY
Grant, award, or other acquisition
|
Direct |
17,430
+19.69%
|
-
|
|
May 21
2024
|
Kathryn C Zoon Director |
SELL
Open market or private sale
|
Direct |
1,089
-2.18%
|
$5,445
$5.78 P/Share
|
|
Apr 07
2024
|
William Hartzel SVP, Bioservices |
SELL
Payment of exercise price or tax liability
|
Direct |
665
-1.9%
|
$1,330
$2.29 P/Share
|
|
Apr 07
2024
|
Coleen Glessner EVP, Quality & Ethics, and CPL |
SELL
Payment of exercise price or tax liability
|
Direct |
585
-0.35%
|
$1,170
$2.29 P/Share
|
|
Mar 05
2024
|
William Hartzel SVP, Bioservices |
SELL
Payment of exercise price or tax liability
|
Direct |
346
-0.98%
|
$1,038
$3.41 P/Share
|
|
Mar 01
2024
|
Jennifer Lynne Fox EVP, Ext Aff, GC, Corp Sec |
SELL
Payment of exercise price or tax liability
|
Direct |
703
-0.4%
|
$2,109
$3.39 P/Share
|
|
Mar 01
2024
|
Richard S Lindahl EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
684
-0.43%
|
$2,052
$3.39 P/Share
|
|
Mar 01
2024
|
Paul Anthony Williams SVP, Products Business |
SELL
Payment of exercise price or tax liability
|
Direct |
137
-0.55%
|
$411
$3.39 P/Share
|
|
Mar 01
2024
|
Coleen Glessner EVP, Quality & Ethics, and CPL |
SELL
Payment of exercise price or tax liability
|
Direct |
381
-0.23%
|
$1,143
$3.39 P/Share
|
|
Feb 29
2024
|
Jennifer Lynne Fox EVP, Ext Aff, GC, Corp Sec |
SELL
Payment of exercise price or tax liability
|
Direct |
4,103
-2.3%
|
$12,309
$3.23 P/Share
|
|
Feb 29
2024
|
Richard S Lindahl EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,037
-5.36%
|
$27,111
$3.23 P/Share
|
|
Feb 29
2024
|
Paul Anthony Williams SVP, Products Business |
SELL
Payment of exercise price or tax liability
|
Direct |
450
-1.77%
|
$1,350
$3.23 P/Share
|
|
Feb 23
2024
|
Paul Anthony Williams SVP, Products Business |
SELL
Payment of exercise price or tax liability
|
Direct |
105
-0.41%
|
$210
$2.74 P/Share
|
|
Feb 23
2024
|
Richard S Lindahl EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
517
-0.31%
|
$1,034
$2.74 P/Share
|
|
Feb 23
2024
|
Jennifer Lynne Fox EVP, Ext Aff, GC, Corp Sec |
SELL
Payment of exercise price or tax liability
|
Direct |
229
-0.13%
|
$458
$2.74 P/Share
|
|
Feb 21
2024
|
Richard S Lindahl EVP, Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
4,012
-2.32%
|
$8,024
$2.71 P/Share
|
|
Nov 13
2023
|
Paul Anthony Williams SVP, Products Business |
SELL
Payment of exercise price or tax liability
|
Direct |
566
-2.17%
|
$566
$1.82 P/Share
|
|
Nov 11
2023
|
William Hartzel SVP, Bioservices |
SELL
Payment of exercise price or tax liability
|
Direct |
632
-1.76%
|
$1,264
$2.0 P/Share
|
|
Nov 11
2023
|
Jennifer Lynne Fox EVP, Ext Aff, GC, Corp Sec |
SELL
Payment of exercise price or tax liability
|
Direct |
413
-0.23%
|
$826
$2.0 P/Share
|
|
Oct 03
2023
|
Neal Franklin Fowler Director |
BUY
Grant, award, or other acquisition
|
Direct |
118,670
+50.0%
|
-
|
|
Oct 03
2023
|
Donald W De Golyer Director |
BUY
Grant, award, or other acquisition
|
Direct |
118,670
+50.0%
|
-
|
|
Jul 08
2023
|
Paul Anthony Williams SVP, Products Business |
SELL
Payment of exercise price or tax liability
|
Direct |
85
-0.32%
|
-
|
|
Jun 09
2023
|
Robert Kramer President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
212,308
+19.06%
|
-
|
|
Jun 09
2023
|
Adam Havey EVP, Business Operations |
BUY
Grant, award, or other acquisition
|
Direct |
73,847
+19.22%
|
-
|
|
Jun 09
2023
|
Richard S Lindahl EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
73,847
+19.37%
|
-
|
|
Jun 09
2023
|
Jennifer Lynne Fox EVP, Ext Aff, GC, Corp Sec |
BUY
Grant, award, or other acquisition
|
Direct |
73,847
+18.74%
|
-
|
|
Jun 09
2023
|
Coleen Glessner EVP, Quality & Ethics, and CPL |
BUY
Grant, award, or other acquisition
|
Direct |
46,155
+12.97%
|
-
|
|
Jun 09
2023
|
Paul Anthony Williams SVP, Products Business |
BUY
Grant, award, or other acquisition
|
Direct |
13,847
+23.7%
|
-
|
|
Jun 02
2023
|
Kathryn C Zoon Director |
SELL
Open market or private sale
|
Direct |
1,830
-3.53%
|
$14,640
$8.35 P/Share
|
|
May 25
2023
|
Kathryn C Zoon Director |
SELL
Open market or private sale
|
Direct |
1,700
-3.18%
|
$13,600
$8.38 P/Share
|
|
May 25
2023
|
Kathryn C Zoon Director |
BUY
Grant, award, or other acquisition
|
Direct |
33,847
+38.75%
|
-
|